David Vermijlen

List of Publications by Year
in descending order

46 papers	2,581 citations	201575 27 h-index	233338 45 g-index
48 all docs	48 docs citations	48 times ranked	3328 citing authors

#	Article	IF	Citations
1	Microbial exposure during early human development primes fetal immune cells. Cell, 2021, 184, 3394-3409.e20.	13.5	141
2	Untargeted metabolomics approach to discriminate mistletoe commercial products. Scientific Reports, 2021, 11, 14205.	1.6	10
3	Effector VÎ³9VÎ´2 T cell response to congenital Toxoplasma gondii infection. JCI Insight, 2021, 6, .	2.3	5
4	Characterization of Adaptive-like Î³Î´ T Cells in Ugandan Infants during Primary Cytomegalovirus Infection. Viruses, 2021, 13, 1987.	1.5	6
5	Characterization of the Î³Î´ Tâ€cell compartment during infancy reveals clear differences between the early neonatal period and 2Âyears of age. Immunology and Cell Biology, 2020, 98, 79-87.	1.0	25
6	Fetal public VÎ³9VÎ´2 T cells expand and gain potent cytotoxic functions early after birth. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18638-18648.	3.3	43
7	The human fetal thymus generates invariant effector Î³Î´ T cells. Journal of Experimental Medicine, 2020, 217, .	4.2	57
8	Innate and adaptive Î³Î´ T cells: How, when, and why. Immunological Reviews, 2020, 298, 99-116.	2.8	46
9	Mistletoe-Extract Drugs Stimulate Anti-Cancer VÎ³9VÎ´2 T Cells. Cells, 2020, 9, 1560.	1.8	9
10	TCR Sequencing Reveals the Distinct Development of Fetal and Adult Human VÎ³9VÎ´2 T Cells. Journal of Immunology, 2019, 203, 1468-1479.	0.4	48
11	Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells. Cancer Immunology Research, 2019, 7, 552-558.	1.6	67
12	Î³Î´ T cell responses: How many ligands will it take till we know?. Seminars in Cell and Developmental Biology, 2018, 84, 75-86.	2.3	84
13	Assessment of tumor-infiltrating TCRVÎ³9VÎ´2Î³Î´lymphocyte abundance by deconvolution of human cancers microarrays. OncoImmunology, 2017, 6, e1284723.	2.1	134
14	Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities. OncoImmunology, 2017, 6, e1283460.	2.1	22
15	The checkpoint for agonist selection precedes conventional selection in human thymus. Science Immunology, 2017, 2, .	5.6	40
16	Human papillomavirus oncoproteins induce a reorganization of epithelial-associated Î³Î´ T cells promoting tumor formation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9056-E9065.	3.3	46
17	Plasma Levels of Macrophage Migration Inhibitory Factor and d-Dopachrome Tautomerase Show a Highly Specific Profile in Early Life. Frontiers in Immunology, 2017, 8, 26.	2.2	29
18	The Checkpoint for Agonist Selection Precedes Conventional Selection in Human Thymus. Blood, 2016, 128, 860-860.	0.6	0

#	Article	IF	Citations
19	Effector VÎ³9VÎ´2 T cells dominate the human fetal Î³Î´ T-cell repertoire. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E556-65.	3.3	183
20	Î³Î´ T Cells Confer Protection against Murine Cytomegalovirus (MCMV). PLoS Pathogens, 2015, 11, e1004702.	2.1	62
21	Do PI3-kinase mutations drive T cells insane?. Cellular and Molecular Immunology, 2014, 11, 320-322.	4.8	2
22	Ontogeny of Innate T Lymphocytes Ã¢â‚¬â€œ Some Innate Lymphocytes are More Innate than Others. Frontiers in Immunology, 2014, 5, 486.	2.2	74
23	Immunity to Cytomegalovirus in Early Life. Frontiers in Immunology, 2014, 5, 552.	2.2	47
24	IL-23R and TCR signaling drives the generation of neonatal VÎ³9VÎ´2 T cells expressing high levels of cytotoxic mediators and producing IFN-Î³ and IL-17. Journal of Leukocyte Biology, 2011, 89, 743-752.	1.5	72
25	Human cytomegalovirus elicits fetal Î³Î´ T cell responses in utero. Journal of Experimental Medicine, 2010, 207, 807-821.	4.2	176
26	Functionally Mature CD4 and CD8 TCRÎ±Î² Cells Are Generated in OP9-DL1 Cultures from Human CD34+ Hematopoietic Cells. Journal of Immunology, 2009, 183, 4859-4870.	0.4	46
27	Distinct Cytokine-Driven Responses of Activated Blood Î³Î´ T Cells: Insights into Unconventional T Cell Pleiotropy. Journal of Immunology, 2007, 178, 4304-4314.	0.4	128
28	Targeting Human Î³Î´ T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer. Cancer Research, 2007, 67, 7450-7457.	0.4	443
29	The Integration of Conventional and Unconventional T Cells that Characterizes Cellâ€Mediated Responses. Advances in Immunology, 2005, 87, 27-59.	1.1	69
30	Pit cells exclusively kill P815 tumor cells by the perforin/granzyme pathway. Comparative Hepatology, 2004, 3, S58.	0.9	3
31	High-density oligonucleotide array analysis reveals extensive differences between freshly isolated blood and hepatic natural killer cells. European Journal of Immunology, 2004, 34, 2529-2540.	1.6	15
32	Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis. International Journal of Cancer, 2004, 112, 793-802.	2.3	57
33	CC531s colon carcinoma cells induce apoptosis in rat hepatic endothelial cells by the Fas/FasL-mediated pathway. Liver International, 2003, 23, 283-293.	1.9	19
34	Effect of resuscitative mild hypothermia on glutamate and dopamine release, apoptosis and ischaemic brain damage in the endothelin-1 rat model for focal cerebral ischaemia. Journal of Neurochemistry, 2003, 87, 66-75.	2.1	48
35	Comments on Augmentation of local antitumor immunity in liver by interleukin-2 gene transfer via portal vein: A possible explanation for contradictory in vivo and vitro results of interleukin-2 treatment in a rat model of colon carcinoma metastasis. Cancer Gene Therapy, 2003, 10, 432-433.	2.2	0
36	Is the presence of interleukin-2 receptor alpha in the serum of colorectal liver metastases patients derived from hepatic natural killer cells?. Cancer Immunology, Immunotherapy, 2002, 51, 291-292.	2.0	1

#	ARTICLE	IF	CITATIONS
37	MHC class I expression protects rat colon carcinoma cells from hepatic natural killer cell-mediated apoptosis and cytolysis, by blocking the perforin/granzyme pathway. Comparative Hepatology, 2002, 1, 2.	0.9	13
38	Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. Journal of Leukocyte Biology, 2002, 72, 668-76.	1.5	78
39	Perforin and granzyme B induce apoptosis in FasL-resistant colon carcinoma cells. Cancer Immunology, Immunotherapy, 2001, 50, 212-217.	2.0	21
40	Rat Hepatic Natural Killer Cells (Pit Cells) Express mRNA and Protein Similar to in Vitro Interleukin-2 Activated Spleen Natural Killer Cells. Cellular Immunology, 2001, 210, 41-48.	1.4	19
41	Organization of Telomeres During the Cell and Life Cycles of Trypanosoma brucei. Journal of Eukaryotic Microbiology, 2001, 48, 221-226.	0.8	23
42	On the cell biology of pit cells, the liver-specific NK cells. World Journal of Gastroenterology, 2000, 6, 1.	1.4	29
43	Participation of CD45, NKR-P1A and ANK61 antigen in rat hepatic NK cell (pit cell)mediated target cell cytotoxicity. World Journal of Gastroenterology, 2000, 6, 546-552.	1.4	5
44	Pit cells (hepatic natural killer cells) of the rat induce apoptosis in colon carcinoma cells by the perforin/granzyme pathway. Hepatology, 1999, 29, 51-56.	3.6	44
45	Involvement of LFA-1 in hepatic NK cell (pit cell)-mediated cytolysis and apoptosis of colon carcinoma cells. Journal of Hepatology, 1999, 31, 110-116.	1.8	22
46	On the Function of Pit Cells, the Liver-Specific Natural Killer Cells. Seminars in Liver Disease, 1997, 17, 265-286.	1.8	65